Compare QS & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QS | MMED |
|---|---|---|
| Founded | 2010 | 1983 |
| Country | United States | United States |
| Employees | N/A | 2800 |
| Industry | Auto Parts:O.E.M. | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.3B |
| IPO Year | 2020 | 2026 |
| Metric | QS | MMED |
|---|---|---|
| Price | $4.92 | $16.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $9.38 | ★ $22.56 |
| AVG Volume (30 Days) | ★ 24.2M | 1.2M |
| Earning Date | 04-22-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.15 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $15.99 |
| Revenue Next Year | $1,827.70 | $10.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.97 | $10.65 |
| 52 Week High | $19.07 | $17.86 |
| Indicator | QS | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 28.53 | 63.33 |
| Support Level | N/A | $14.70 |
| Resistance Level | $7.21 | N/A |
| Average True Range (ATR) | 0.39 | 0.90 |
| MACD | -0.12 | 0.04 |
| Stochastic Oscillator | 7.02 | 73.31 |
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional nodes. The company operates in one operating segment only.
Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform of simple and clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and Smart Multiple Daily Injection (MDI) Systems. It derives revenue from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. Geographically, it operates in the USA and the Rest of World, with the majority of revenue derived from the Rest of World.